Clinical Trial

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

Study acronym: DME
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-01-16; most recent amendment 2025-03-04.
Status change: Recruiting → Active, Not Recruiting 2024-12-19
Status change: Not Yet Recruiting → Recruiting 2023-03-28
Trial Details
NCT Number NCT05698329
Lead Sponsor AiViva BioPharma, Inc.
Conditions Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
Enrollment 19 participants
Start Date 2023-03-02
Primary Completion 2025-03-03 (estimated)
Study Completion 2025-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-06